Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gynecologic 1

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Cytopenia 2Carcinoma, Squamous Cell 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Malignant Neoplasmas 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Anus Neoplasms 1Anemia, Refractory 1Advanced Solid Tumors 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × ON 01910 × Clear all
NCT00856791 2017-07-21

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Traws Pharma, Inc.

Phase 2 Completed
1 enrolled 5 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01538537 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡